

**Fluid and Electrolytes Management in Children Undergoing Neurosurgery**

Chi[a](https://orcid.org/0000-0003-1628-3845)ra Robba **D**, Isr[ael](https://orcid.org/0000-0003-2496-6646) Rosenstein, and Federico Bilotta **o** 

# **10**

## **Key Points**

- The fuid management plan for children undergoing neurosurgical procedures should consider preoperative assessment, correction of existing defcit, calculation of intraoperative requirements and management thereof, postoperative management of the imbalances, and fuid therapy monitoring.
- Among children, a fall in blood pressure is usually a late sign of hypovolemia, and it should be rapidly corrected to maintain cardiac output and cerebral perfusion. Slower correction of dehydration, without the signs of hypovolemia, is acceptable.
- Avoid, if possible, colloids and glucose infusion. In the case of hypernatremia as a consequence of pituitary surgery (such as diabetes insipidus), infusion of 5% glucose solution may be considered.
- Electrolytes dysregulation, such as hyponatremia or hypernatremia, and  $K<sup>+</sup>$  alterations are associated with worsening of the outcome.
- Attention should be paid to postoperative complications, particularly after surgery for

C. Robba  $(\boxtimes)$ 

Neurocritical Care Unit, Addenbrooke's Hospital, Cambridge University, Cambridge, UK

I. Rosenstein · F. Bilotta

sellar lesions (diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion, cerebral salt wasting syndrome).

## **10.1 Introduction**

Advances in neurosurgical techniques have changed the face of pediatric neurosurgical management, leading to generally improved outcomes. However, with the increasing demand, complexity, and improvement of care for children undergoing neurosurgical procedures, there is an increased need to develop guidelines to improve the level of care and assure uniform patient management. In particular, fuid and electrolytes management in the pediatric neurosurgical population requires careful attention to the intravenous (IV) fluid administration and close monitoring of fuid balance and assessment of the clinical status of the patient to prevent and correct perioperative complications. Neurosurgical patients are usually complex and often need a large number of fuids and hemo-components as well as postoperative monitoring in an intensive care setting. Moreover, several pathophysiological processes occur in this group of patients that make them vulnerable to peculiar electrolyte and fluid disturbances, including syndrome of inappropriate antidiuretic hormone (SIADH) secretion, cerebral salt wasting syndrome (CSWS), and cranial diabetes insipidus (DI). This chapter

Department of Anesthesiology and Critical Care, Policlinico Umberto I Hospital, La Sapienza University of Rome, Rome, Italy

<sup>©</sup> The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2021 165 G. P. Rath (ed.), *Fundamentals of Pediatric Neuroanesthesia*, [https://doi.org/10.1007/978-981-16-3376-8\\_10](https://doi.org/10.1007/978-981-16-3376-8_10#DOI)

will review the main principles for fluid and electrolytes management in the pediatric population undergoing neurosurgical procedures.

# **10.2 General Considerations**

Management of infants and children posted for neurosurgical procedures requires careful considerations of the unique challenges they present with. There are several important differences between the procedures performed in pediatric neurosurgical patients and those performed in the adult population, which are usually due to the anatomo-physiologic peculiarities of children. The types and characteristics of the central nervous system (CNS) tumors seen in the pediatric population are different from those in adults. Also, the management of some conditions (such as hydrocephalus) is much more challenging from both clinical and surgical perspectives, particularly when its onset is in infancy or childhood [\[1](#page-11-0)].

Because of the particular anatomical characteristics of the pediatric population, including a more compliant (viscoelastic) and not fully ossifed skull, injuries to the brain mass (including tumors, hemorrhages, etc.) tend to progress indolently when compared with adult lesions. Additionally, considerations like the development of the spinal cord and associations with congenital disorders in pediatric patients also impact the decision-making process perioperatively compared to the adults.

Several anatomical, physiological, and anesthetic implications have to be taken into account (Table [10.1](#page-1-0)). A higher percentage of total body water in the pediatric population than adults makes them vulnerable to develop serious morbidity caused by fuid and electrolytic imbalance. They need a large volume of distribution for water-soluble medications, and low fat and muscle content provides a small reservoir for drugs that depend on redistribution into these tissues for their metabolism and the execution of their effect. Therefore, water-soluble drugs require larger doses for clinical effect (such as antibiotics and muscle relaxants), while drugs like thiopen-

<span id="page-1-0"></span>**Table 10.1** Peculiar characteristics of neonatal physiology regarding fuid and electrolytes

Neonatal	Characteristics regarding fluid and
physiologic variables	electrolytes
Body water	• Term neonates: $75\%$ (40%)
percentage and	ECF, 35% ICF)
distribution	• Preterm neonates (23 weeks):
	90% water (60% ECF, 30%
	ICF)
	• Adults: $60\%$ water (20% ECF,
	40% ICF)
<b>Fluid losses</b>	• Skin (70%) and respiratory
	tract $(30\%)$ are the major
	sources of insensible water
	losses (IWL) in neonates
	• Preterm infants have a
	generally higher IWL
Cardiovascular	• Reduced cardiac contractility
physiology	(low contractile mass/gram of
	cardiac tissue)
	• Reduced ability to $\uparrow$ stroke
	volume
	· Dependence on heart rate
	(↑ HR) to ↑ cardiac output
	(Treppe effect)
	• High sensitivity to
	hypovolemia and anesthetic
	agents
Renal function	• 25% functionality at birth with
	maturation by 2 years of age
	$\bullet$ T <sub>0.5</sub> of drugs excreted by
	glomerular filtration is
	prolonged
	• Normal urine osmolality:
	50–600 mEq/L in preterm and
	$(50-?)$ 800 mEq/L in term
	infants

*ECF* extracellular fuid, *ICF* intracellular fuid

tal (redistribution into fat) and fentanyl (redistribution into the muscle) have a longer clinical effect.

Moreover, renal and cardiovascular physiology and fuid losses present some differences in the pediatric population compared with adults (Table [10.1](#page-1-0)), making them more vulnerable to fuid dysregulation. In children, the fall in blood pressure is usually a late sign of hypovolemia, and hence, it is to be corrected rapidly to maintain effective cardiac output and cerebral perfusion.

In addition to all of the above considerations, in-depth knowledge of anticipated major possible adverse events is also essential in managing some of the unique surgical challenges. Fluid and electrolyte imbalance can also increase morbidity and mortality, and its prevention and prompt treatment should be a priority concern in pediatric neurosurgery.

## **10.3 Choice of Fluid During Pediatric Neurosurgery**

Planning for fuid management in neurosurgical cases is extremely important, and communication between the surgeon and the anesthesiologist in this regard must be clear. In general, the target is to ensure euvolemia, avoiding both hypovolemia and hypervolemia and consequently hypoperfusion of the brain and other organs, and attenuate edema. Crystalloids should be the frst choice, and in particular, 0.9% normal saline is commonly used because of its slight hyperosmolality (308 mOsm/L), which can help in attenuating the occurrence of brain edema (Table [10.2](#page-2-0)) [\[2](#page-11-1)]. Although there is no absolute contraindication, caution must be exercised with the use of colloids (hydroxyethyl starch). A recently published meta-analysis concluded that the established adverse effect profle of colloids such as renal injury and coagulopathy were not observed with their perioperative administration in noncardiac surgeries [[3\]](#page-11-2).

In patients with intracranial hypertension, osmotherapy using mannitol or hypertonic saline (3% or higher concentration) should be considered in order to reduce intracranial pressure (ICP). However, if possible, it is important to avoid using hypertonic solutions if a central line is not available so to avoid the risk of phlebitis. Attention should also be paid to the administra-

tion of diuretics (such as furosemide), which can be used to induce systemic diuresis, improve overall cerebral water transport, and decrease cerebrospinal fuid (CSF), but they can also determine hypovolemia and dehydration and reduced cerebral perfusion pressure (CPP).

Hypotonic saline solutions (including 0.45% NaCl, 0.45% NaCl +5% dextrose, 0.18% NaCl +10% dextrose, 0.18% NaCl +4% dextrose, and 10% dextrose solutions) should be used with extreme caution in neurosurgical patients, as they can worsen cerebral edema, and should only be used to treat acute hypernatremia (Na >150 mEq/L) [[4\]](#page-11-3). In particular, small children and neonates are more susceptible to hypoglycemia than adults, which may occur after preoperative fasting. Thus, when initiating fuid management in neonates, the use of 0.9% NaCl and dextrose should be considered. Complications of hyperglycemia in neonates and preterm infants include dehydration due to diuresis and electrolyte disturbances and an increased risk of hypoxic-ischemic central nervous system (CNS) damage and have to be strictly avoided [\[5](#page-11-4)]. The current anesthetic practice involves dextrose solutions at a lower concentration (1–2%) instead of the traditional use of 5% solutions [\[6](#page-11-5)]. In children older than 5 years, in those who have a low risk of fasting-induced hypoglycemia, or in patients with documented hyperglycemia, 0.9% NaCl without dextrose is usually the standard of care [\[7](#page-11-6)]. Although a hyperglycemic response during surgery and anesthesia is anticipated (increased sympathetic system activity and gluconeogenesis), such a response may not occur in all patients and makes children especially prone to hypoglycemia. The incidence of intraoperative hypoglycemia has been estimated at 0–2.5% and

<span id="page-2-0"></span>Table 10.2 Commonly used intravenous fluids

<b>Types</b>	$Na+$	$K^+$	$Cl-$	$Ca^{2+}$	$Mg^{2+}$	Acetate lactate	Glucose	Phosphate	Osmolality
<b>NS</b>	154		154						308
RL		4	109	3		q			274
Isolyte P	26	21	21			24			
Plasmalyte	140	5	98			27			295
Albumin $5\%$	150	< 2.5	100						330
Hetastarch	154		154						310

*NS* normal saline, *RL* Ringer's lactate

is generally seen with longer fasting periods (8–19 h). Hence, it becomes essential to monitor blood glucose levels intermittently when fasting is prolonged and glucose is not being supplemented intraoperatively [[8\]](#page-11-7).

Fluid management for neurosurgical procedures can be divided into several phases [[9\]](#page-11-8):

- Fluid considerations before surgery.
- Preoperative assessment for fluid deficits and methods for correction.
- Estimating the requirements for maintenance fluids.
- Management of other losses (blood and third space loss) during surgery.
- Postoperative fuid management and modalities to monitor fuid therapy.

## **10.3.1 Fluid Considerations Before Surgery**

In the preoperative phase, fuids are best administered through the oral/enteral route. The literature is not clear about which is the safest preoperative fasting practice in infants. Some authors consider it safe to anesthetize a child 3 h after the last breastfeeding; some suggest this concept is valid only in infants under 6 months of age, and others would allow surgery 4 h after the last breastfeeding [\[10\]](#page-11-9). It is generally accepted that children aged 6 months or older should safely be allowed to have clear fuids 2 h before surgery and that withholding of solid food should be done 8 h before surgery. This is essential to prevent dehydration in the child and, at the same time, reduce the risk of hypoglycemia and aspiration. Under 6 months of age, breast milk is allowed up to 4 h before surgery [\[11\]](#page-11-10).

## **10.3.2 Assessment and Correction of Fluid Defcit**

The preoperative assessment of the pediatric population undergoing neurosurgical procedures should take into account several factors.

An accurate collection of information about the patient's past medical history is necessary, focusing on congenital or acquired diseases that can increase the risk for dehydration or electrolyte imbalance (heart or kidney diseases, burns, etc.). Physical examination should include the weighting of the child (one of the most important criteria to assess the fuid balance in children) and the characteristics of the skin and mucosa (including dry mucosa, edema, and altered skin turgor). Clinical signs due to dehydration are tardive, in particular the hypotension. Therefore, trying to calculate the water deficit precisely using clinical signs may result in inaccuracies. In mild dehydration, the only clinical signs/symptoms may generally be just an increased thirst with dry mucosal membranes; in moderate dehydration, tachypnea, cool and pale peripheries with prolongation of capillary refll times, sunken eyes, reduced skin turgor, and low urine output can be useful additional clinical signs/symptoms. Finally, in severe dehydration, in addition to the signs of moderate dehydration, the child may be irritable and/or lethargic and have severe hypotension with deep acidotic breathing, which is late premorbid signs (Table [10.3](#page-4-0)) [[12–](#page-11-11)[14](#page-11-12)].

Laboratory tests should be obtained alongside the accurate clinical assessment, including serum electrolytes and plasma osmolality, blood urea, serum creatinine, urine electrolytes, and specifc gravity, and, if necessary, arterial blood gases (ABGs).

Patients undergoing minor and elective surgery usually have only a minor fuid defcit, which is usually not necessary to correct. For major surgery, an initial bolus of 10 ml/kg of isotonic crystalloid (0.9% normal saline) or Ringer lactate or Hartmann's solution should be given in the first hour to correct the fluid deficit. The fluid normally used to replace this deficit should be isotonic, in particular, 0.9% sodium chloride. Should hypovolemia be present, a bolus of 10–20 ml/kg of an isotonic fuid must be administered and repeated as per Advanced Pediatric Life Support (APLS) guidelines [[15\]](#page-11-13).

	Mild	Moderate	Severe
Grade of dehydration	$\left( < 3\% \right)$ water loss)	$(3-10\%$ water loss)	$(>10\%$ water loss)
General	Alert	Thirsty, lethargic	Cold, sweaty, limp
Pulse	Normal rate and volume	Rapid and weak	Rapid, feeble
Systolic pressure	Normal	Normal	Low
Respiratory rate	Normal	Increased, deep	Deep
Dry mouth	No	Yes	Yes
Eyes	Normal	Sunken	Sunken
Anterior Fontanelle	Normal	Sunken	Very sunken
Skin turgor	Normal (recoils instantly)	Reduced $(1-2s)$	Severely reduced $(>2 s)$
Capillary refill	Not prolonged	Slightly prolonged	Prolonged
Neurological deterioration	N <sub>0</sub>	<b>Drowsiness</b>	Severe
Urine output	Normal	Reduced	Reduced
Deficit	$30 - 50$ ml/kg	$60 - 100$ ml/kg	$>100$ ml/kg

<span id="page-4-0"></span>**Table 10.3** Signs and symptoms of dehydration

<span id="page-4-1"></span>**Table 10.4** Holliday and Segar recommendations for fuid management (4-2-1 rule)

Body weight (kg)	Daily fluid requirement
$0 - 10$	$4 \text{ ml/kg/h}$
$10 - 20$	$40$ ml/h + 2 ml/kg/h above 10 kg
>20	$60$ ml/h + 1 ml/kg/h above 20 kg

## **10.3.3 Maintenance Fluid Requirements**

Fluid requirements due to fasting should be replaced according to the recommendations of Holliday and Segar for children and infants over 4 weeks of age, using the child's body weight (Table [10.4](#page-4-1)) [\[16](#page-11-14)]. According to Furman et al., the total amount of hourly maintenance requirements multiplied by hours of fuid restriction should be administered by giving 50% in the frst hour and 25% during each of the next 2 h [\[17](#page-11-15)]. This management strategy was further modifed by Berry et al., as they suggested the administration of a salty solution bolus during the frst hour of the surgery (25 ml/kg for children 3 years old and younger, 15 ml/kg for older than 4 years) [\[18](#page-11-16)].

However, this formula should be just considered as a starting point only. Every individual child should always be monitored for response to fuid therapy, and adjustments should be made accordingly; in particular, clinical parameters to be assessed include heart rate, blood pressure, and capillary refll time.

<span id="page-4-2"></span>**Table 10.5** Fluid requirements for neonates

Newborn term	Daily fluid requirement (ml/kg)
Day 1	$50 - 60$
Day 2	80
$>$ Day 7	$100 - 150$

In term neonates (>36-week gestational age), maintenance fuid requirements are reduced in the first few days after birth (Table  $10.5$ ). The normal infant will lose up to 10–15% of its body weight in water during this time. For the older children, the 4–2-1 rule (Holliday and Segar method) is followed. Certain conditions like burns, radiant heaters or phototherapy pyrexia, or excessive sweating result in hypermetabolic states resulting in increased requirements in maintenance fuids [\[19](#page-11-17), [20](#page-11-18)].

During neurosurgical procedures, most children may be given fuids without dextrose. The maintenance fuid most commonly used during neurosurgery is an isotonic crystalloid, 0.9% sodium chloride. However, blood glucose and electrolytes should always be monitored, especially in long procedures, major surgery, or pituitary surgery. Perioperative dextrose (1–2.5% dextrose in Ringer's lactate solution) was shown to increase blood glucose in pediatric patients during surgery, which returned to normal levels about 1 h after surgery. The use of 2.5% solution was shown to yield a much greater increase in blood glucose, compared with 1% solution [[21\]](#page-11-19).

# **10.3.4 Management of Other Losses During Surgery**

Generally, replacement of all losses during surgery should be done with 0.9% sodium chloride, or eventually Ringer lactate/Hartmann's solution, while colloids should be used only when deemed necessary. Intraoperative losses include third space loss and blood loss. During surgery, third space loss occurs due to extravasation of fuids from the intravascular compartments out to the tissues around the surgery site, and they should be replaced. It is generally accepted that superfcial surgeries, including ophthalmic and neurosurgeries, result in the least amount of third space loss estimated at 1–2 ml/kg/h [\[22](#page-12-0)].

Even in this phase, it is important to assess clinical signs like heart rate, blood pressure, and capillary refll time to ensure adequate replacement. In case of bleeding, blood products transfusion should be considered. The determinants for blood transfusion are based on clinical signs, estimated blood volume (Table [10.6\)](#page-5-0), preoperative hemoglobin and hematocrit values, and coexisting illnesses.

According to a study, a hemoglobin threshold of 7 gm/dL for red blood cell transfusion can decrease transfusion requirements without increasing adverse outcomes in critically ill children [[23\]](#page-12-1). A fall in hematocrit of up to 25% from baseline values may be acceptable in children aged more than 3 months; however, in children with cyanotic congenital heart disease or severe respiratory diseases, a higher hematocrit target should be used to maintain appropriate tissue oxygenation. In infants younger than 3 months of age, it is not clear which is the hemoglobin and hematocrit threshold to consider for transfusion, but blood administration should be individually considered, according to the clinical

<span id="page-5-0"></span>**Table 10.6** The estimated blood volume in neonates and infants

Age	Estimated blood volume (ml/kg)
Premature neonates	$95 - 100$
Full-term neonates	$85 - 90$
<b>Infants</b>	80

conditions and the gestational age. However, mildly low hemoglobin and hematocrit values could be acceptable in small, older preterm infants [\[24](#page-12-2), [25\]](#page-12-3).

## **10.3.5 Postoperative Fluid Management and Monitoring of Fluid Therapy**

Regarding postoperative fuid management (Table [10.7](#page-5-1)**)**, it should be considered that surgery, pain, nausea, and vomiting are all potential causes of dehydration and ADH release, as well as other peculiar complications related to neurosurgical procedures, including DI or other electrolyte disturbances. The literature is not clear about which is the correct maintenance fuid rate during the postoperative period. Holliday and Segar's formula may be followed; isotonic fuids may be used to replace ongoing losses from drains or nasogastric tubes, with or without added electrolytes. Serum electrolytes, as well as hemoglobin and hematocrit, should be measured preand postoperatively. Moreover, children should be weighed prior and after the prescription and administration of fuids [\[21](#page-11-19)]. During the postoperative period, serum electrolytes should be monitored every 24 h in all children on IV fuids (or more frequently if abnormal). Particular attention is paid to patients who underwent pituitary surgery and who are vulnerable to electrolytic complications. Fluid monitoring should include a fuid input/output chart, urine output monitored hourly and replaced every 2–4 h. Apart from routine clinical parameters, advanced parameters

<span id="page-5-1"></span>**Table 10.7** Goals of postoperative fluid therapy

Parameter	Target
Urine output	$1-3$ ml/kg/h
Allowable weight loss	$1-2\%$ per day in first week
Urine specific gravity	$1005 - 1015$
Euglycemia	$75 - 100$ mg/dl
Normonatremia	135-145 mEq/L
Normokalemia	$4-5$ mEq/L
Prevention of failure	Absence of edema/
	dehydration/hepatomegaly

like dynamic indices of fuid responsiveness like stroke volume variation (SVV), pulse pressure variation (PPV), and plethysmograph variability index (PVI) may be employed whenever available. Although they have been validated in adults, the data available for the pediatric population is limited due to the anatomical and physiological variations in cardiorespiratory parameters that make their efficacy limited  $[26, 27]$  $[26, 27]$  $[26, 27]$  $[26, 27]$ .

# **10.4 General Principles for Electrolytes Management**

Neurosurgical patients receiving IV fuids should have their electrolytes checked daily by capillary sampling or venous blood gas analysis. Hyponatremia is the most common electrolytic disorder in this group of patients, and if SIADH or CSWS occurs, sodium may fall very rapidly, and the treatment becomes a clinical emergency. In general, any neurosurgical patient with a drop in sodium of more than 4 mEq/L since the last measurement or a Na<sup>+</sup> <131 mEq/L should have an urgent clinical assessment. Repeat electrolytes and ABG analysis are to be done to confrm hyponatremia, and appropriate treatment is to be instituted. Any patient with  $Na<sup>+</sup> < 135$  mEq/L on routine blood tests should be reviewed urgently, including the assessment of fuid balance, IV or enteral fuids, and replacement of Na+ losses [\[28](#page-12-6)]. Finally, patients with extraventricular drainage (EVD) in situ should have their electrolytes monitored twice a week.

#### **10.5 Sodium Disturbances**

#### **10.5.1 Hyponatremia**

Hyponatremia may occur in up to 20% of patients in the postoperative period and reach up to 50% of neurosurgical patients. The early signs of hyponatremia are nonspecifc, and often the frst presenting symptoms are neurological deterioration, seizures, or respiratory arrest. Headache is considered an early and common sign of hyponatremia, but this sign might not be obvious in young children. Initial symptoms may also include nausea or vomiting; and progress to confusion, seizures, stupor, and coma as hyponatremia worsens. Finally, severe hyponatremia may result in brain swelling (cerebral edema) and symptoms related to increased ICP. The magnitude of the symptoms is related to both the severity and the rate at which serum sodium levels drop [\[29](#page-12-7)]. Hyponatremia can increase mortality, which is signifcantly higher and directly related to the severity of electrolyte disturbance. Therefore, aggressive treatment as a medical emergency and pediatric intensive care admission is mandatory precaution [[30\]](#page-12-8).

There are several conditions which can lead to hyponatremia in the pediatric population (Table [10.8\)](#page-7-0); however, in neurosurgical patients, the main causes of hyponatremia are the SIADH, resulting from excessive water retention after ADH secretion dysfunction, or the salt-losing brain syndrome, characterized by hyponatremia, polyuria, and severe dehydration [\[31\]](#page-12-9). Pituitary tumors are at higher risk for developing both these conditions, whereas in tumors not involving the hypothalamo-pituitary axis, SIADH occurs commonly. As the management of both these conditions is vastly different, accurate diagnosis and clinical and laboratory criteria are most essential (Table [10.9\)](#page-7-1). Physiologically, ADH is secreted in cases of high plasma osmolality and decreased effective blood volume, which is detected by the osmoreceptors and baroreceptors in the aortic arch, carotid sinus, left atrium, and hypothalamus. ADH acts on the distal convoluted tubule and collecting ducts in the kidney in order to reabsorb water without reabsorbing solute.

Inappropriate ADH secretion occurs when this process happens in response to non-osmotic stimuli (Table [10.10\)](#page-7-2). The main risk factors are stress, cerebral injury, mechanical ventilation, pain, and several drugs, including anesthetic agents and antiepileptic drugs. Patients affected by SIADH present with euvolemia or hypovolemia with hyponatremia, and therefore the clinical management should be based on Na<sup>+</sup> replacement and fuid restriction.

In the salt wasting syndrome, there is an excessive release of the natriuretic peptide, which

Reduced total body sodium	Clinical presentations
Extrarenal	Vomiting, diarrhea
	Fluid sequestration (sepsis, peritonitis, pancreatitis)
	Cutaneous losses (burns)
	Ventriculostomy drainage
Renal	Cerebral salt wasting syndrome
	Diuretics (osmotic/non-osmotic)
	Tubulointerstitial diseases
	Adrenal insufficiency
	Congenital adrenal hyperplasia, Addison's disease
	Renal diseases (obstructive uropathy, nephritis, pyelonephritis, renal tubular acidosis)
Increased total body	Congestive heart failure
sodium	<b>Cirrhosis</b>
	Nephrotic syndrome
	Renal failure
Normal total body sodium	<b>SIADH</b>
	Glucocorticoid deficiency
	Hypothyroidism
	Infantile water intoxication
	Abusive water intoxication

<span id="page-7-0"></span>**Table 10.8** Causes of hyponatremia in the pediatric population

<span id="page-7-1"></span>**Table 10.9** Differential diagnosis between SIADH and CSWS

Parameters	<b>SIADH</b>	<b>CSWS</b>
Extracellular fluid	Normal to	Low
volume	high	Negative
Fluid balance	Positive or	Increased or
Urine volume	neutral	normal
Central venous	Decreased or	Low
pressure	normal	High
Urine $Na+$	Normal to	$(>40 \text{ mEq/L})$
	high	
	High	
	$(20 -$	
	$40 \text{ mEq/L}$	

*SIADH* syndrome of inappropriate antidiuretic hormone, *CSWS* cerebral salt wasting syndrome

leads to primary natriuresis and volume depletion, and therefore patients present with hypovolemia and hyponatremia. Thus, given the severe dehydration risk, an aggressive volume replacement with an isotonic solution and increased sodium supply is necessary.

In general, asymptomatic hyponatremia should be treated with enteral fuids as tolerated or with intravenous 0.9% sodium chloride solution and, eventually, fuid intake restriction if the child presents normal or increased volume. Patients with hyponatremic encephalopathy (seizure, coma) should be aggressively treated with <span id="page-7-2"></span>**Table 10.10** The causes of syndrome of inappropriate antidiuretic hormone (SIADH) secretion



an infusion of hypertonic 3% sodium chloride solution. 1 ml/kg of 3% sodium chloride will normally raise the serum sodium by 1 mEq/L, and attention should be paid to the rate of Na+ increase, which should not be higher than 1–2 mEq/L/h to avoid complications such as pontine myelinolysis. Hypertonic saline should be administered via a central vein, but it is important not to delay sodium administration for the insertion of the central venous line.

The amount of Na<sup>+</sup> required can be calculated as:

mmol of Na<sup>+</sup> required =  $(130 -$  present serum Na<sup>+</sup>  $) \times 0.6 \times$  Weight (kg)

Sodium should be raised aggressively until serum Na<sup>+</sup> reaches 125–130 mEq/L, or after clinical improvement. A slower Na+ correction should take place at this stage, and a 0.9% sodium chloride solution should be used. The addition of dextrose to this solution is still controversial, as generating hyperglycemia might worsen brain injury, and thus, should be considered on a case to case basis. During Na<sup>+</sup> replacement, patients should be monitored for signs of increased ICP, and electrolytes should be rechecked every 4 h until Na<sup>+</sup> is >130 mEq/L and, then, at least twice a day for the following 48 h. Finally, particular attention should be paid to patients with EVDs in situ, who might be more prone to hyponatremia due to sodium loss in CSF. The Na+ levels in CSF are similar to those of plasma, and when the EVD drainage rate is  $>10$  ml/h, Na<sup>+</sup> loss should be monitored and accurately replaced [[32–](#page-12-10)[34\]](#page-12-11).

#### **10.5.2 Hypernatremia**

In hospitalized children, hypernatremia (serum  $Na<sup>+</sup> > 150$  mEq/L) commonly occurs due to excessive water loss, restricted intake, or an inability to respond to thirst. It is, therefore, generally related to a systemic dehydrated status (Table [10.11\)](#page-8-0). The magnitude of the hypernatremia signs is more severe when it develops rapidly or when serum  $Na^+ > 160$  mEq/L, while chronic hypernatremia is often well tolerated. The severity of dehydration might be underestimated if clinical signs alone are used, compared to weight loss.

Improvement of hydration and establishing euvolemia should be targeted with 0.9% sodium chloride, given in boluses of 20 ml/kg. Once the initial fuid replacement is done, complete correction of hypernatremia should be done very slowly over at least 48 h to prevent cerebral edema, seizures, and brain injury. The correction rate should be no more than 12 mmol/kg/day and

done with 0.45% or 0.9% sodium chloride with dextrose [[35\]](#page-12-12).

#### **10.5.3 Diabetes Insipidus (DI)**

Neurosurgical patients, especially with suprasellar tumors, are at high risk for many postoperative complications, including DI (Table [10.12\)](#page-8-1). The defciency of ADH secretion

<span id="page-8-0"></span>**Table 10.11** Causes of hypernatremia in the pediatric population

Causes of			
hypernatremia	Clinical presentation		
Low total body sodium			
Extrarenal	Vomit, diarrhea, profuse sweating		
losses	Osmotic diuresis (mannitol, glucose,		
Renal losses	urea)		
Inadequate	<b>Insufficient</b> lactation		
intake			
Increased total body sodium			
Increased Na	Excessive administration of Na <sup>+</sup> ,		
intake	near-drowning (seawater)		
Normal total body sodium			
Extrarenal	Respiratory insensible losses,		
losses	dermal insensible losses (fever,		
Renal	burns, radiant warmers,		
	phototherapy)		
	Diabetes insipidus		

<span id="page-8-1"></span>**Table 10.12** Causes of diabetes insipidus



results in intravascular solvent loss, polyuria, and, dehydration, with consequent hypernatremia, which can occur within the frst postoperative hours. In patients who underwent pituitary surgery, DI should always be suspected, and if serum Na<sup>+</sup> level increases over 150 mEq/L, with urinary sodium levels below 20 mEq/L, polyuria, and dehydration. The therapy for DI is desmopressin, a synthetic ADH analog, which should be administered early to prevent metabolic complications described above. This medication can be administered intravenously, orally, or intranasally. Hypotonic saline solutions (e.g., 0.45% NaCl, 0.45% NaCl +5% dextrose, 0.18% NaCl +10% dextrose, 0.18% NaCl +4% dextrose, and 10% dextrose solutions) should only be used to treat active hypernatre-mia (Na >150 mEq/L) [\[36\]](#page-12-13).

#### **10.5.4 Hyperkalemia**

Hyperkalemia (serum  $K^+$  >5.5 mEq/L in infants and >6 mEq/L in neonates) can cause general skeletal muscle weakness and substantial ECG changes, especially when serum K+ >7 mEq/L. Hyperkalemia is most commonly an artifact due to either hemolysis or release of K+ during clot formation in the specimen tube. Other causes of hypopotassemia are drugs, including β-blockers and digitalis, myonecrosis, and acidosis, as well as renal disorders or failure [[37\]](#page-12-14). First-line treatment of hyperkalemia should include the administration of 100 μg/kg of 10% calcium gluconate. The second line of treatment consists of administration of sodium bicarbonate (1–2 mmol/kg), an infusion of 0.3–0.5 mg/kg/h of glucose with 1 unit of insulin for every 5 gm of glucose added, or an infusion of 2.5–5 mg of nebulized salbutamol  $(5 \mu g/kg \text{ in neonates}, IV)$  to increase intracellular shift of potassium. Finally, the removal of potassium from the body is achieved by administering 125– 250 mg/kg calcium resonium rectally or orally,

by using either furosemide (1 mg/kg), dialysis, or hemofiltration.

#### **10.5.5 Hypokalemia**

Hypokalemia (serum  $K^+$  <3.5 mEq/L) is usually caused by diuretic therapy. In intensive care and perioperative settings, additional causes include nasogastric suctioning, magnesium defciency, and alkalosis or loss of  $K<sup>+</sup>$  as a consequence of vomiting/diarrhea. Children are usually asymptomatic until  $K^+$  reaches 2.5 mEq/L, and then they might present with muscular symptoms such as cramps, cardiological complications (including arrhythmias, reduced cardiac contractility, ECG alterations like U waves, loss of T waves, and QT prolongation), and neurological deterioration. Hypokalemia is associated with poor outcomes in patients with aneurysmal subarachnoid hemorrhage and therefore should be aggressively treated [[38\]](#page-12-15). This is also true for symptomatic hypokalemic children [\[39](#page-12-16)]. Management should focus on reversing the transcellular shifts (alkalosis) and on potassium replacement. Potassium can be administered orally (3–5 mmol/kg/day) or intravenously (recommended in severe hypokalemia, i.e., serum  $K^+$ <3 mEq/L). Potassium correction should not be faster than 0.25 mmol/kg/h while using a maximal peripheral concentration of 40 mEq/L of KCl. When a rapid correction is being done, it is essential to carry out the administration via a central line while monitoring the patient in the intensive care unit [\[38](#page-12-15)].

#### **10.5.6 Hypocalcemia**

Hypocalcemia (defined as corrected total  $Ca<sup>2+</sup>$ <2 mEq/L, or <1.5 mEq/L in neonates) may produce various symptoms, including perioral, fnger, and toe paresthesia, spasm, cardiac alterations including prolonged QT interval, and reduced cardiac contractility. Immediate treatment includes 10% calcium gluconate (0.5 ml/kg, up to a maximum of 20 ml over 10 min) or a solution of 10% calcium chloride (0.2 ml/kg, up to a maximum of 10 ml over 10 min), possibly through a central venous route. Newborns are prone to hypocalcemia due to physiologically lower albumin concentration, a normal fall occurring after birth, which later rises after the second day, and maternal diabetes mellitus. Other causes include encephalopathy, renal failure, DiGeorge syndrome, and disordered maternal metabolism [[38\]](#page-12-15).

#### **10.5.7 Hypercalcemia**

Hypercalcemia presents with a low incidence (<1% of hospitalized patients), and most of the cases are caused by hyperparathyroidism or malignant tumors. More rare causes include thyrotoxicosis and drugs. Presentation is nonspecifc, including cardiovascular (hypotension/ hypovolemia and shortened QT interval on ECG), renal (polyuria, nephrocalcinosis), and neurological alterations. Patients require treatment if symptomatic, or if ionized  $Ca^{2+} > 3.5$  mEq/L (14 mg/dL). Hypercalcemia can also produce hypercalciuria, which results in osmotic diuresis and hypovolemia. These patients are volume depleted and, therefore, require saline infusions; furosemide can be used to enhance excretion, but it can exacerbate hypovolemia and hypotension.

#### **10.5.8 Hypophosphatemia**

Hypophosphatemia is seen when serum phosphate levels fall below  $0.8 \text{ mEq/L}$  (or  $\langle 2.7 \text{ mg} \rangle$ dL) and occurs in 17–28% of postoperative patients. When glucose moves into cells, phosphate usually follows it, and thus, glucose overloading is the most common cause of hypophosphatemia in hospitalized patients [[35\]](#page-12-12). Hypophosphatemia is often clinically asymptomatic, and even at levels of <1.0 mg/dL, it may not produce any obvious effects. However, common symptoms include muscle weakness and respiratory depression, and therefore, phosphate levels are to be monitored with attention in the postoperative period. Hypophosphatemia can lower cardiac output (CO), and patients with low CO and heart failure may respond to supplementation [\[38](#page-12-15)]. Phosphate replacement can be started intravenously if levels are very low, but when phosphate levels are higher than 2.0 mg/dL, a replacement can be given orally.

#### **10.5.9 Hyperphosphatemia**

It usually occurs after renal insufficiency (decreased secretion), widespread cell death related to tumor lysis, or rhabdomyolysis. Sucralfate calcium acetate tablets or antacids can be used to reduce serum levels.

#### **10.5.10 Hypomagnesemia**

Hypomagnesemia is found in 15% of ward patients and 60% of ICU patients. Main causes include other electrolyte abnormalities (hypokalemia, hypophosphatemia, hyponatremia, hypocalcemia), drugs (diuretics, furosemide, aminoglycosides, digitalis, amphotericin, cyclosporine), diarrhea, alcohol, and diabetes. The clinical fndings include cardiac manifestations, ischemia, arrhythmia, and neurological deterioration. Hypomagnesemia has been shown to be studied in relation to vasospasm in patients with SAH, in both animal and human models. In a study including 283 SAH patients, 4 days of magnesium treatment compared with normal saline showed a favorable trend in the development of delayed cerebral ischemia (reduced by 34%) and resulted in a better outcome at 3 months [[40\]](#page-12-17). Still, its role in a SAH is considered controversial.

### **10.5.11 Hypermagnesemia**

Hypermagnesemia is found in up to 5% of hospitalized patients. The risk factors include massive hemolysis, renal adrenal insufficiency, hyperparathyroidism, and lithium toxicity. Magnesium is a calcium channel blocker, and thus, the prominent effects of hypermagnesemia are cardiac (ECG alteration, including prolonged AV conduction, heart block, and cardiac arrest). To treat hypermagnesemia, IV calcium gluconate (1 mg over 2–3 min) should be given, and eventually, if not effective, dialysis should be started. With preserved renal function, aggressive fuid resuscitation and furosemide are appropriate as well.

#### **10.6 Conclusions**

Recognizing the diverse nature of pediatric neurosurgery complications is imperative for appropriate patient management during the perioperative periods. Disturbances in salts and water balances are relatively common in children, and present diagnostic and therapeutic challenges, especially after brain surgeries for suprasellar and pituitary tumors. Sodium disturbances, and in particular hyponatremia, are the most common and critical disturbances, even if DI is commonly encountered as well. A proper fuid balance assessment and a prompt diagnosis are mandatory to improve the outcome of the pediatric neurosurgical population.

**Confict of Interest** None.

#### **References**

- <span id="page-11-0"></span>1. Rekate HL. The pediatric neurosurgical patient: the challenge of growing up. Semin Pediatr Neurol. 2009;16(1):2–8.
- <span id="page-11-1"></span>2. Bilotta F, Rosa G. Saline or albumin for fuid resuscitation in traumatic brain injury. N Engl J Med. 2007;357(25):2635. author reply 2635-2636
- <span id="page-11-2"></span>3. Thy M, Montmayeur J, Julien-Marsollier F, Michelet D, Brasher C, Dahmani S, et al. Safety and efficacy of perioperative administration of hydroxyethyl starch in children undergoing surgery: a systematic review and meta-analysis. Eur J Anaesthesiol. 2018;35(7):484–95.
- <span id="page-11-3"></span>4. Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child. 2006;91(10):828–35.
- <span id="page-11-4"></span>5. Leelanukrom R, Cunliffe M. Intraoperative fuid and glucose management in children. Pediatr Anesth. 2000;10(4):353–9.
- <span id="page-11-5"></span>6. Mikawa K, Maekawa N, Goto R, Tanaka O, Yaku H, Obara H. Effects of exogenous intravenous glucose on

plasma glucose and lipid homeostasis in anesthetized children. Anesthesiology. 1991;74(6):1017–22.

- <span id="page-11-6"></span>7. SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, George Institute for International Health, Myburgh J, Cooper DJ, et al. Saline or albumin for fuid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357(9):874–84.
- <span id="page-11-7"></span>8. Welborn LG, McGill WA, Hannallah RS, Nisselson CL, Ruttimann UE, Hicks JM. Perioperative blood glucose concentrations in pediatric outpatients. Anesthesiology. 1986;65(5):543–7.
- <span id="page-11-8"></span>9. Perioperative\_Fluid\_Management\_2007.pdf [Internet]. [cited 2020 Nov 21] [https://www.apagbi.](https://www.apagbi.org.uk/sites/default/files/inline-files/Perioperative_Fluid_Management_2007.pdf) [org.uk/sites/default/files/inline-files/Perioperative\\_](https://www.apagbi.org.uk/sites/default/files/inline-files/Perioperative_Fluid_Management_2007.pdf) [Fluid\\_Management\\_2007.pdf](https://www.apagbi.org.uk/sites/default/files/inline-files/Perioperative_Fluid_Management_2007.pdf)
- <span id="page-11-9"></span>10. Cook-Sather SD, Nicolson SC, Schreiner MS, Maxwell LG, Park JJ, Gallagher PR, et al. Proponents of liberalized fasting guidelines. Anesthesiology. 2005;102(1):236–7. author reply 238
- <span id="page-11-10"></span>11. Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Søreide E, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2011;28(8):556–69.
- <span id="page-11-11"></span>12. Paut O, Lacroix F. Recent developments in the perioperative fuid management for the paediatric patient. Curr Opin Anaesthesiol. 2006;19(3):268–77.
- 13. Zornow MH, Prough DS. Fluid management in patients with traumatic brain injury. New Horiz Baltim Md. 1995;3(3):488–98.
- <span id="page-11-12"></span>14. Bissonnette B, Dalens BJ. Renal function, acid-base and electrolyte homeostasis. In: principles & practice of pediatric anesthesia. London: McGraw-Hill Education - Europe; 2002.
- <span id="page-11-13"></span>15. Advanced Paediatric Life Support: A Practical Approach to Emergencies, 6th Edition | Wiley [Internet]. 6th ed. John Wiley & Sons, Ltd; 2016 [cited 2020 Nov 21].
- <span id="page-11-14"></span>16. Oh TH. Formulas for calculating fuid maintenance requirements. Anesthesiology. 1980;53(4):351.
- <span id="page-11-15"></span>17. Furman EB, Roman DG, Lemmer LA, Hairabet J, Jasinska M, Laver MB. Specifc therapy in water, electrolyte and blood-volume replacement during pediatric surgery. Anesthesiology. 1975;42(2):187–93.
- <span id="page-11-16"></span>18. Berry FA. Practical aspects of fuid and electrolyte therapy. In: Anesthetic management of diffcult and routine pediatric patients. 2nd Ed ed. New York: Churchill Livingstone; 1986. p. 107–35.
- <span id="page-11-17"></span>19. Cooper DJ, Myles PS, McDermott FT, Murray LJ, Laidlaw J, Cooper G, et al. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA. 2004;291(11):1350–7.
- <span id="page-11-18"></span>20. Dubick MA, Wade CE. A review of the effcacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and in humans. J Trauma. 1994;36(3):323–30.
- <span id="page-11-19"></span>21. Datta PK, Aravindan A. Glucose for children during surgery: pros, cons, and protocols: a post-

graduate educational review. Anesth Essays Res. 2017;11(3):539–43.

- <span id="page-12-0"></span>22. Cunliffe M. Fluid and electrolyte management in children. BJA CEPD Rev. 2003;3(1):1–4.
- <span id="page-12-1"></span>23. Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609–19.
- <span id="page-12-2"></span>24. Kelly A, Machovec, Craig WB. Pediatric fuid management. In: Kaye AD, editor. Essentials of Pediatric Anesthesiology. Illustrated edition. Cambridge University Press; 2014. p. 298–304.
- <span id="page-12-3"></span>25. Mahanna E, McGrade H, Afshinnik A, Iwuchukwu I, Sherma AK, Sabharwal V. Management of sodium abnormalities in the neurosurgical intensive care unit. Curr Anesthesiol Rep. 2015;4(5):387–92.
- <span id="page-12-4"></span>26. Yi L, Liu Z, Qiao L, Wan C, Mu D. Does stroke volume variation predict fuid responsiveness in children: a systematic review and meta-analysis. PLoS One. 2017;12(5) [cited 2020 Nov 21]. [https://www.ncbi.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428964/) [nlm.nih.gov/pmc/articles/PMC5428964/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428964/)
- <span id="page-12-5"></span>27. Lee J-H, Kim E-H, Jang Y-E, Kim H-S, Kim J-T. Fluid responsiveness in the pediatric population. Korean J Anesthesiol. 2019;72(5):429–40.
- <span id="page-12-6"></span>28. Moritz ML, Ayus JC. Preventing neurological complications from dysnatremias in children. Pediatr Nephrol Berl Ger. 2005;20(12):1687–700.
- <span id="page-12-7"></span>29. Upadhyay UM, Gormley WB. Etiology and management of hyponatremia in neurosurgical patients. J Intensive Care Med. 2012;27(3):139–44.
- <span id="page-12-8"></span>30. Sherlock M, O'Sullivan E, Agha A, Behan LA, Rawluk D, Brennan P, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol. 2006;64(3):250-4.
- <span id="page-12-9"></span>31. Rahman M, Friedman WA. Hyponatremia in neurosurgical patients: clinical guidelines develop-

ment. Neurosurgery. 2009;65(5):925–35. discussion 935-936

- <span id="page-12-10"></span>32. Bettinelli A, Longoni L, Tammaro F, Faré PB, Garzoni L, Bianchetti MG. Renal salt-wasting syndrome in children with intracranial disorders. Pediatr Nephrol Berl Ger. 2012;27(5):733–9.
- 33. Holliday MA, Segar WE. The maintenance need for water in parenteral fuid therapy. Pediatrics. 1957;19(5):823–32.
- <span id="page-12-11"></span>34. Moritz ML. Syndrome of inappropriate antidiuresis and cerebral salt wasting syndrome: are they different and does it matter? Pediatr Nephrol Berl Ger. 2012;27(5):689–93.
- <span id="page-12-12"></span>35. Moritz ML, Ayus JC. The changing pattern of hypernatremia in hospitalized children. Pediatrics. 1999;104(3 Pt 1):435–9.
- <span id="page-12-13"></span>36. Yamada S, Fukuhara N, Oyama K, Takeshita A, Takeuchi Y, Ito J, et al. Surgical outcome in 90 patients with craniopharyngioma: an evaluation of transsphenoidal surgery. World Neurosurg. 2010;74(2–3):320–30.
- <span id="page-12-14"></span>37. Alimohamadi M, Saghafnia M, Alikhani F, Danial Z, Shirani M, Amirjamshidi A. Impact of electrolyte imbalances on the outcome of aneurysmal subarachnoid hemorrhage: a prospective study. Asian J Neurosurg. 2016;11(1):29–33.
- <span id="page-12-15"></span>38. Bilotta F, Guerra C, Rosa G. Update on anesthesia for craniotomy. Curr Opin Anaesthesiol. 2013;26(5):517–22.
- <span id="page-12-16"></span>39. Daly K, Farrington E. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment. J Pediatr Health Care. 2013;27(6):486–96. quiz 497–8
- <span id="page-12-17"></span>40. van den Bergh Walter M. Magnesium sulfate in aneurysmal subarachnoid hemorrhage. Stroke. 2005;36(5):1011–5.